Latest filing published 02 Aug 2024 for Processa Pharmaceuticals, Inc.. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
James H. Stanker is a declared insider of Processa Pharmaceuticals, Inc., with filings sourced from SEC (Form 4). The record holds 8 filings, for trades running from 21 June 2021 to 5 April 2024.
No open-market sale appears; the market trades are 1 purchase worth €5,717. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 4 share grants and 3 option exercises.
On 2 August 2024 came the latest disclosure, an option exercise in Processa Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 1,944 days ago, on 22 June 2021. Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations